---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-064549"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:38:06.587507+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics appoints Thomas McCourt and Darren Cline to Board of Directors

## Summary
- Board expanded from 8 to 10 members; McCourt (Class II) and Cline (Class I) appointed effective March 6, 2023.
- Both deemed independent; McCourt joins Compensation Committee, Cline joins Audit Committee.
- Each receives annual retainer of $40,000; McCourt $5,000 for Comp Committee, Cline $7,500 for Audit Committee.
- Each granted option to purchase 22,000 shares, vesting monthly over three years.
- Standard indemnification agreements entered into with both new directors.

## SEC filing metadata
- accession: 0001193125-23-064549
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312523064549/0001193125-23-064549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312523064549/d479466d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-064549
- JSON: https://secwatch.observer/filing/0001193125-23-064549.json
- Plain text: https://secwatch.observer/filing/0001193125-23-064549.txt

## Key facts
- Executive change
  Darren Cline was appointed as Director at PLIANT THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312523064549/0001193125-23-064549-index.htm
- Executive change
  Thomas McCourt was appointed as Director at PLIANT THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: the Board appointed, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), each of Thomas McCourt and Darren Cline to fill the Class II and Class I vacancies on the Board, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000119312523064549/0001193125-23-064549-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.